Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study-Reference-Cited by-同舟云学术

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study

Published:2012-01 Issue:1 Volume:12 Page:27-35
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Molina Jean-Michel,LaMarca Anthony,Andrade-Villanueva Jaime,Clotet Bonaventura,Clumeck Nathan,Liu Ya-Pei,Zhong Lijie,Margot Nicolas,Cheng Andrew K,Chuck Steven L

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference22 articles.

1. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137);Shimura;J Virol,2008

2. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients;DeJesus;J Acquir Immune Defic Syndr,2006

3. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure;Mathias;Clin Pharmacol Ther,2009

4. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial;Lennox;Lancet,2009

5. Raltegravir with optimized background therapy for resistant HIV-1 infection;Steigbigel;N Engl J Med,2008

Cited by 160 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. US cost-utility model of lenacapavir plus optimized background regimen (OBR) vs fostemsavir plus OBR and ibalizumab plus OBR for people with HIV with multidrug resistance;Journal of Managed Care & Specialty Pharmacy;2024-09

2. The differential effects of integrase strand transfer inhibitors and efavirenz on neuropsychiatric conditions and brain imaging in HIV-positive men who have sex with men;Biosafety and Health;2024-08

3. Chronic Liver Enzyme Elevation and Use of Contemporary ARVs Among People With HIV;Open Forum Infectious Diseases;2024-06

4. Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study;Frontiers in Cellular and Infection Microbiology;2023-06-26

5. The evolution of clinical study design in heavily treatment-experienced persons with HIV: A critical review;Antiviral Therapy;2023-05-22